1. Androgen receptor and MYC equilibration centralizes on developmental super-enhancer.
- Author
-
Guo H, Wu Y, Nouri M, Spisak S, Russo JW, Sowalsky AG, Pomerantz MM, Wei Z, Korthauer K, Seo JH, Wang L, Arai S, Freedman ML, He HH, Chen S, and Balk SP
- Subjects
- Androgens metabolism, Cell Line, Tumor, Chromatin genetics, Chromatin metabolism, Gene Expression Regulation, Neoplastic, Humans, Male, Oncogene Protein p55(v-myc) metabolism, Promoter Regions, Genetic, Prostatic Neoplasms metabolism, Receptors, Androgen metabolism, Signal Transduction, Enhancer Elements, Genetic, Oncogene Protein p55(v-myc) genetics, Receptors, Androgen genetics
- Abstract
Androgen receptor (AR) in prostate cancer (PCa) can drive transcriptional repression of multiple genes including MYC, and supraphysiological androgen is effective in some patients. Here, we show that this repression is independent of AR chromatin binding and driven by coactivator redistribution, and through chromatin conformation capture methods show disruption of the interaction between the MYC super-enhancer within the PCAT1 gene and the MYC promoter. Conversely, androgen deprivation in vitro and in vivo increases MYC expression. In parallel, global AR activity is suppressed by MYC overexpression, consistent with coactivator redistribution. These suppressive effects of AR and MYC are mitigated at shared AR/MYC binding sites, which also have markedly higher levels of H3K27 acetylation, indicating enrichment for functional enhancers. These findings demonstrate an intricate balance between AR and MYC, and indicate that increased MYC in response to androgen deprivation contributes to castration-resistant PCa, while decreased MYC may contribute to responses to supraphysiological androgen therapy., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF